u/Ill_Mousse_4240

The FDA are officially adding aging and longevity as a focus point for research and medicine.

Thought I would share for any of those who want to see aging as a treatable condition!

Ever had food poisoning that seemed to wreck your gut for good? Researchers think they found part of why.

A team out of Mayo Clinic looked at people who developed IBS after a Campylobacter infection (the classic bad chicken or contaminated produce bug) and found that a chunk of them had way higher gut protease activity, basically an overactive digestive enzyme (a protein-breaking chemical) that can damage the gut lining and trigger pain. What separated the high and low activity groups: a single gut bacterium, Alistipes putredinis, was completely missing in the high activity group but showed up reliably in healthy guts.

The mechanism. This bacterium and some relatives make an enzyme that converts bilirubin (a pigment from broken down red blood cells) into a form that directly blocks that overactive digestive enzyme. No bacterium, no brake.

They then proved this was causal in mice, not just a correlation. Germ free mice (raised with zero gut bacteria) had way higher enzyme activity than normal mice. Giving them stool transplants from healthy human donors calmed it down, but only when that donor's microbiome actually contained Alistipes putredinis. Adding the bacterium alone to a "bad" microbiome sample reproduced the calming effect, and directly dosing mice with the bilirubin byproduct did the same thing.

Limitations. The human side of this is a modest cohort (52 IBS patients), and every causal experiment, colonization, transplants, bilirubin dosing, was done in mice, not people. No probiotic or supplement version of this has been tested on humans yet, so do not go buy anything based on this.

TL;DR: People with IBS after food poisoning who have unusually high gut enzyme activity are commonly missing a specific bacterium that normally keeps that enzyme in check by processing bilirubin, and mouse experiments confirmed putting the bacterium (or its bilirubin byproduct) back reverses the effect, but the causal proof is mouse only, sitting on top of a 52 person human study, not a proven human treatment yet.

---

*Written by a human, formatted by AI*

The Core Issue

Alcohol use disorder (AUD) is brutally hard to treat. The existing drugs (naltrexone, acamprosate, disulfiram) have modest efficacy at best, and more than 60 percent of people relapse after treatment. Researchers have been hunting for new angles, and the gut has become one of the more interesting ones.

The Finding

A review pooled results from 11 clinical trials testing whether fixing gut bacteria, or targeting the hormones gut bacteria help control, changes drinking behavior. In one trial, a single fecal microbiota transplant (FMT, transferring stool bacteria from a healthy donor) given to men with alcohol related cirrhosis led to craving reduction in 9 of 10 recipients versus 3 of 10 on placebo within two weeks. Separately, five trials tested GLP-1 drugs (the same hormone-mimicking class as Ozempic and Wegovy), and three of them found real, statistically significant drops in heavy drinking days.

Why it Matters

Five of the eleven trials found gut bacteria imbalance (dysbiosis) to be a common feature in people with AUD, which supports treating the gut and the addiction as connected problems instead of separate ones. This matters even more for people with alcohol related liver disease, since three of the trials specifically involved that group, and current drug options for them are limited.

Limitations of Study

This is a review of small, mostly single site trials, not one big new study. Individual trial sizes ranged from just 16 to 151 people, several key results (including one trial's 6 month abstinence numbers) were not statistically significant, and two of the five GLP-1 trials moved in the right direction but missed statistical significance. The authors themselves say larger controlled trials are needed before any of this becomes standard care.

Interesting Statistics

• FMT trial: craving reduction in 9 of 10 patients vs 3 of 10 on placebo (p = 0.02), and far fewer serious alcohol related complications (1 vs 7 events, p = 0.02)

• A separate FMT cohort had a lower relapse rate than corticosteroid treated patients (28.6% vs 53.8%) and took roughly twice as long to relapse (436 days vs 197 days)

• A probiotic strain (Lactobacillus rhamnosus GG) got 66.7% of treated patients with alcohol related hepatitis down to social drinking or abstinence at 6 months, versus 18.2% on placebo

• One semaglutide trial cut heavy drinking days by 41.1% versus 26.4% in a matched comparison group over 26 weeks

• Dulaglutide, another GLP-1 drug, cut weekly alcohol intake by 29% versus placebo after 12 weeks

• The whole review covered 779 participants across all 11 trials combined

Useful Takeaways

None of this is an approved treatment for alcohol use disorder, and nobody should go ask a doctor for a fecal transplant or an off label GLP-1 prescription based on this alone. But if you or someone you know is dealing with AUD, especially alongside liver disease, it is worth knowing that gut targeted and hormone targeted therapies are an active area of research, not just diet fads. A large VA funded trial testing semaglutide in over 600 veterans is already underway, with results still years out.

TL;DR: A review of 11 small trials found that fecal transplants, probiotics, and GLP-1 drugs like semaglutide all showed real but inconsistent effects on alcohol cravings and drinking, adding weight to the idea that gut bacteria and the brain are linked in addiction.

---

*Written by a human, formatted by AI*

The standard image of aging treats the body as something that deteriorates more or less together. Hair grays, joints stiffen, memory slips, energy fades. The rate varies from person to person, but within a single body, most people assume their organs and cells are aging in rough synchrony.

A study published in Nature Medicine has tested that assumption against the largest plasma proteomics dataset ever assembled for aging research.

Researchers at Stanford University and collaborating institutions analyzed more than 7,000 plasma proteins from 60,542 people across three independent cohorts. Using the Human Protein Atlas, they linked those proteins to specific cell types and built machine learning models to estimate the biological age of more than 40 distinct cell populations, including neurons, astrocytes, immune cells, endocrine cells, epithelial cells, and muscle cells. Each model was validated independently against separate protein platforms and separate cohorts.

The finding that emerged is not that some people age faster than others, though that is also true. It is that within a single person, different cell types are aging at radically different speeds.

One in four people had at least one cell type aging dramatically faster than their chronological age would predict. Between one and three percent of people had ten or more cell types showing accelerated aging simultaneously. And the specific pattern of which cell types were aging fastest was not random. It predicted, with statistical precision, which diseases each person would develop over the next 15 years.

The Core Issue

Most immune research on aging focuses on decline, but supercentenarians (people aged 110 and older) show an unexpected pattern: a dramatic rise in a rare type of T cell that combines helper and killer functions in one.

The Finding

CD4 CTLs (cytotoxic T cells that carry the CD4 marker, normally associated with immune coordination rather than direct killing) expand sharply around age 100, reaching a median of 17.6% of T cells in supercentenarians. These cells form massive clones, with top clones occupying an average of 33.3% of the CD4 CTL pool. Critically, they show no signs of exhaustion, meaning they remain active and functional rather than burned out from chronic stimulation.

Why it Matters

When researchers checked public TCR databases, CDR3 sequences from these supercentenarian T cell clones matched sequences found in tumor samples, particularly non-small cell lung cancer patients, none of whom shared a known cancer history. This raises the possibility that these cells contribute to tumor immunosurveillance, catching and clearing early threats before they progress. They may also target senescent cells, the aging, malfunctioning cells that accumulate in tissues and drive inflammation.

Limitations of Study

This was a small cohort. The study included only 10 supercentenarians, and TCR sequence matches were based on one chain of the receptor, which is exploratory rather than proof of shared antigen recognition. No direct in-vivo validation was performed.

Interesting Statistics

• CD4 CTLs reach a median of 17.6% of T cells in supercentenarians, compared to much lower levels in people in their 70s to 90s
• Top clones averaged 33.3% occupancy within the CD4 CTL pool, indicating extreme clonal dominance
• Dual TCR alpha chains were found in 7.6% of analyzed T cells, an unusual structural feature
• Activated CD4 CTLs expressed TCRγ genes at roughly half the level seen in dedicated gamma-delta T cells
• CDR3β sequence matches were found across multiple tumor types, with the strongest signal in non-small cell lung cancer

Useful Takeaways

These cells show plasticity, meaning a single clone can shift between different cytokine profiles including Th2-like (IL-4, IL-13) and Tfh-like (IL-21) outputs depending on context. This flexibility may be part of what makes them effective across a range of threats. Researchers describe them as a potential double-edged sword: beneficial when surveilling tumors and clearing senescent tissue, but potentially damaging if misdirected against healthy cells.

TL;DR

Supercentenarians accumulate a rare killer-helper hybrid T cell that may explain exceptional longevity by patrolling for tumors and aging cells, but direct proof of function is still missing.

---

Written by a human, formatted by AI

Abstract

At more than 200 years, the maximum lifespan of the bowhead whale exceeds that of all other mammals. The bowhead is also the second-largest animal on Earth1, reaching over 80,000 kg. Despite its very large number of cells and long lifespan, the bowhead is not highly cancer-prone, an incongruity termed Peto’s paradox2. Here, to understand the mechanisms that underlie the cancer resistance of the bowhead whale, we examined the number of oncogenic hits required for malignant transformation of whale primary fibroblasts. Unexpectedly, bowhead whale fibroblasts required fewer oncogenic hits to undergo malignant transformation than human fibroblasts. However, bowhead whale cells exhibited enhanced DNA double-strand break repair capacity and fidelity, and lower mutation rates than cells of other mammals. We found the cold-inducible RNA-binding protein CIRBP to be highly expressed in bowhead fibroblasts and tissues. Bowhead whale CIRBP enhanced both non-homologous end joining and homologous recombination repair in human cells, reduced micronuclei formation, promoted DNA end protection, and stimulated end joining in vitro. CIRBP overexpression in Drosophila extended lifespan and improved resistance to irradiation. These findings provide evidence supporting the hypothesis that, rather than relying on additional tumour suppressor genes to prevent oncogenesis3,4,5, the bowhead whale maintains genome integrity through enhanced DNA repair. This strategy, which does not eliminate damaged cells but faithfully repairs them, may be contributing to the exceptional longevity and low cancer incidence in the bowhead whale.

This is fascinating and Google Headlines says it would reverse aging and prevent cancer.

Would someone explain it to us and see how feasible it would be?

If this is true it sounds like they are in line for a Nobel Prize?

Crummy link:

"Aug 21, 2026 Biology Cell & Microbiology Biology Biotechnology

New ROOT method charts a path to reversing biological changes once thought irreversible by The Korea Advanced Institute of Science and Technology (KAIST)

edited by Sadie Harley, reviewed by Robert Egan

Editors' notes The GIST

KAIST Develops Core Technology to Reverse Biological Changes Once Thought Irreversible

The ROOT framework for identifying and controlling the cause of irreversible cell-state transitions.

Professor Kwang-Hyun Cho's research team used a logic-based molecular regulatory network to identify the core circuits that sustain irreversible state transitions (the irreversibility kernel), and developed control strategies that either restore cells to their previous state or eliminate irreversibility based on these circuits. Credit: The Korea Advanced Institute of Science and Technology (KAIST)

Once a cell has locked into an abnormal state—the way cancer cells do—can it ever be restored to normal? A KAIST research team led by Professor Kwang-Hyun Cho of the Department of Bio and Brain Engineering has, for the first time, identified the causal circuits responsible for irreversibility in intracellular molecular networks and developed a fundamental control technology called ROOT that can regulate these circuits and restore biological states to their original conditions.

The paper is published in the journal Proceedings of the National Academy of Sciences.

Cells in the human body change their state in response to external stimuli. In many cases, however, these state changes are irreversible, in the sense that cells do not return to their original state even after the stimulus disappears.

Irreversibility is essential for maintaining normal biological processes, such as a cell differentiating into one with a specific function. At the same time, it can also drive disease progression—for example, in epithelial–mesenchymal transition, which gives cancer cells the ability to migrate into and invade surrounding tissue.

Complicating matters, the circuits that maintain these state changes inside a cell are highly intricate: More than a thousand positive feedback loops are woven throughout the network, in which one molecule activates a series of other molecules that in turn reactivate the original molecule. This is similar to the feedback screech produced when a microphone is placed next to a speaker, where sound repeatedly amplifies itself.

Even a change that starts with an external stimulus can persist after the stimulus is gone, simply because the cell's own molecules keep reinforcing one another. Until now, it has been extremely difficult to determine which of these countless circuits is actually responsible for locking a cell into an irreversible state.

Pinpointing the circuits that lock cells in To solve this problem, the team developed ROOT technology, short for Revelation Of the Original circuit of irreversible Transition, which works by representing intracellular regulatory processes as computational logic models and analyzing them through systems biology techniques.

Using ROOT, the research team successfully simulated the process in which cells maintain a signal even after an external stimulus is removed, allowing them to identify a set of core circuits that cause irreversibility, which they defined as the "irreversibility kernel."

Going beyond identifying the cause, the team also proposed two groundbreaking control strategies.

The first, "resetting control," restores a cell to its state before the change while leaving the cell's underlying irreversible property intact—comparable to leaving the lock itself in place but opening the locked door and returning to the starting point.

The second, "reversing control," removes the source of irreversibility itself, allowing a cell to move freely between different states—comparable to disabling the mechanism that automatically locks a door each time it closes, so that afterward the door can be opened and closed again.

Testing ROOT across cell models The team applied the new technique to various biological models, including B-cell differentiation, epithelial–mesenchymal transition in lung cancer, and enterocyte and beta-cell differentiation models based on single-cell transcriptome data. In these models, the ROOT method accurately identified causal circuits that matched known cell-fate determinants.

The team also proposed more effective resetting control strategies, demonstrating that the method can be broadly applied even to models built from real experimental data.

KAIST Develops Core Technology to Reverse Biological Changes Once Thought Irreversible Process of identifying the irreversibility kernel and deriving control strategies using ROOT. Using a logic-based molecular regulatory network of an irreversible biological phenomenon as input, Professor Kwang-Hyun Cho's research team extracted the irreversible state-transition pathway, identified the irreversibility kernel—the core circuit that sustains irreversibility—and, based on this, derived optimal control strategies that either restore cells to their previous state or eliminate irreversibility. Credit: The Korea Advanced Institute of Science and Technology (KAIST)

Restoring abnormal cells instead of removing them

Rather than simply removing cells that have become fixed in an abnormal state, as in cancer or aging, the technology is expected to help identify and control the core circuits that keep cells trapped in that state, enabling new treatment strategies that restore cells to a normal condition.

Cho said, "The core achievement of this study is identifying the causal circuits behind cells that, once changed, do not return to their original state, and developing a technology to control these circuits and restore cells to their previous condition.

"We expect this technology to be used in developing new treatment strategies that restore abnormally fixed cell states—such as those seen in cancer and aging—back to normal."

Publication details Jongwan Kim et al, The structural origin of irreversible transitions in biological networks, Proceedings of the National Academy of Sciences (2026). DOI: 10.1073/pnas.2600800123

Journal information: Proceedings of the National Academy of Sciences

Key concepts state and transition modelingDynamics of networksBiological networksBiological network methods

Who's behind this story? Sadie Harley Sadie Harley BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →

Robert Egan

Provided by The Korea Advanced Institute of Science and Technology (KAIST) ,"